NeoPharm reiterated at strong buy by JMP

NeoPharm, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at a strong buy rating with a $19 price target. The company said the criterion for the second futility analysis was reached in its phase 3 Precise trial of cintredekin besudotox in first recurrence glioblastoma. The study is expected to reach its goal of full enrollment by the end of this year, which could present a potential upside for the company's bottom line and for the stock. Shares of the Lake Forest, Ill., biopharmaceutical company were up 25 cents, or 2.47%, at $10.37 on volume of 170,875 shares versus the three-month running average of 306,591 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.